Pharming Group NV (PHAR NASDAQ) stock market data APIs
$12.8156
0.26(2%)
as of June 15, 2026
Try our APIs with
free plan!
Pharming Group NV Financial Data Overview
Price chart is built with
Anychart
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K" inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Prev. Close
12.8156
Open
13.0725
High
13.1191
Low
12.8025
52 wk Range
9.5354-21.34
Market Cap
923 M
P/E Ratio
68.7895
Shares Outstanding
70 625 K
Revenue
369 M
EPS
-0.07
Beta
0.098
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Pharming Group NV data using free add-ons & libraries
Get Pharming Group NV Fundamental Data
Pharming Group NV Fundamental data includes:
- Net Revenue: 369 M
- EBITDA: 42 282 K
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-07
- EPS/Forecast: 0.01
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pharming Group NV News
New
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Suppl...
Pharming Group Receives EU Approval For Joenja In Rare Immunodeficiency
(RTTNews) - Pharming Group (PHAR) announced that the European Commission granted marketing authorization for Joenja (leniolisib), an oral, selective phosphoinositide 3-kinase (PI3K) delta inhibitor, f...
Pharma Equity Groups datterselskab Reponex tager vigtigt skridt fremad inden for inflammatorisk tarmsygdom med kommende europæisk patentgodkendelse
Pharma Equity Groups datterselskab Reponex tager vigtigt skridt fremad inden for inflammatorisk tarmsygdom med kommende europæisk patentgodkendelse 11. maj 2026 Meddelelse nr. 7 Pharma Equit...
Pharming Group Q1 Earnings Call Highlights
Pharming Group logo Key Points Interested in Pharming Group N.V. Sponsored ADR? Here are five stocks we like better. RUCONEST revenue fell (down ~15% Y/Y) largely due to specialty pharmacy inventory...
Get Pharming Group NV fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
